TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03151486
Drug: JNJ-55308942 0.5 mg
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942 1.5 mg
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942 4 mg
Normalized name: JNJ-55308942
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942 12 mg
Normalized name: JNJ-55308942
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942 36 mg
Normalized name: JNJ-55308942
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942 100 mg
Normalized name: JNJ-55308942
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
Study: NCT03151486
Drug: JNJ-55308942: Fed State
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
Study: NCT00449436
Drug: TRIZIVIR
Normalized name: Trizivir
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRIZIVIR
Study: NCT03151486
Drug: JNJ-55308942: MAD Part
DrugBank: JNJ-55308942 (DB19110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
Study: NCT00332488
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation, 15U/30U, prandial
Study: NCT00332488
Drug: Metformin & Secretagogues
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
Study: NCT00332488
Drug: Technosphere Insulin & Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
Study: NCT03431350
Drug: Niraparib 200 mg
Normalized name: niraparib 200 MG
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive niraparib 200 mg orally.
Study: NCT03431350
Drug: Cetrelimab 240 mg
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive cetrelimab 240 mg IV every 2 weeks.
Study: NCT03431350
Drug: Cetrelimab 480 mg
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive cetrelimab 480 mg IV every 4 weeks.
Study: NCT03431350
Drug: Abiraterone acetate 1000 mg
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive AA 1000 mg orally.
Study: NCT03431350
Drug: Prednisone 5 mg
Normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive prednisone 5 mg orally.
Study: NCT03412877
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study: NCT03412877
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
Study: NCT02503982
Drug: prophylactic Valganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
Study: NCT01919346
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01960348
Drug: patisiran (ALN-TTR02)
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered by intravenous (IV) infusion
Study: NCT01960348
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by intravenous (IV) infusion
Study: NCT00555997
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
Study: NCT00130910
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400mg x 3 first dose observed
Study: NCT02533349
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg, 1 tablet, 1time a day
Study: NCT01087749
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
Study: NCT01087749
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
Study: NCT01087749
Drug: Eprosartan
Normalized name: Eprosartan
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
Study: NCT02151630
Drug: Salicylic Acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00349622
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.
Study: NCT03393884
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6 IV over 1 hour on Day 1 of each cycle
Study: NCT03393884
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2 IV over 3 hours on Day 1 of each cycle
Study: NCT02880007
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
Study: NCT03395808
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
Study: NCT00462670
Drug: OPC-41061(Tolvaptan)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0, 15mg of OPC-41061 per day for 7days p.o. administration
Study: NCT02966002
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00544063
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00544063
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02409342
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
Study: NCT02179853
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First two doses IV followed by SQ dosing
Study: NCT00214032
Drug: Pycnogenol
Normalized name: Pycnogenol
DrugBank: Maritime pine extract (DB15786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pycnogenol 300 mg daily
Study: NCT04252287
Drug: Canagliflozin 100 mg
Normalized name: canagliflozin 100 MG
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
Study: NCT04046133
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
Study: NCT01392716
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 intravenously once a week for 4 weeks
Study: NCT03372733
Drug: control olive oil (COO)
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day
Study: NCT03372733
Drug: palmitoleate-rich oil (PLO)
Normalized name: palmitoleate
DrugBank: Cetyl palmitoleate (DB19456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day
Study: NCT01290211
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc 300 mg BID x 5 days
Study: NCT01290211
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc 300 mg QD x 5 days
Study: NCT01290211
Drug: Fosamprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study: NCT01290211
Drug: Maraviroc + Fosamprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study: NCT02282410
Drug: ADVATE
Normalized name: Advate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
Study: NCT02396537
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intranasally prior to Midazolam administration.
Study: NCT02396537
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
Study: NCT03153111
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: macitentan 10 mg; film-coated tablet; oral use
Study: NCT03891524
Drug: JNJ-70033093 25 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
Study: NCT03891524
Drug: JNJ-70033093 50 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
Study: NCT03891524
Drug: JNJ-70033093 100 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
Study: NCT03891524
Drug: JNJ-70033093 200 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
Study: NCT03891524
Drug: Enoxaparin 40 mg
Normalized name: enoxaparin 40 mg/0.4 mL injectable solution
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Study: NCT03062059
Drug: Intravesical 2000mg/52.6ml gemcitabine instillation
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
Study: NCT00063102
Drug: ABT-751
Normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00629317
Drug: Methyl Aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
Study: NCT02361177
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Study: NCT04418180
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
Study: NCT02434523
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
Study: NCT01427192
Drug: acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg bid
Study: NCT02571283
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered 20 minutes+ before additional medications.
Study: NCT02571283
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered 20 minutes or more after Exparel is administered.
Study: NCT02518191
Drug: GnRHa
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
Study: NCT00003423
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003423
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003423
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003423
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003423
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003423
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003423
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01487304
Drug: Marketed low dose hormone replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A low dose of marketed HRT products prescribed at the discretion of the treating physician
Study: NCT03067103
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
Study: NCT03067103
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
Study: NCT00670696
Drug: tetracaine gel
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tetracaine gel
Study: NCT02675140
Drug: ZENTEL
Normalized name: ALBENDAZOLE 400 mg ORAL TABLET [ZENTEL]
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
Study: NCT02675140
Drug: ZENTEL and Vitamin A Soft Capsules
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
Study: NCT01132196
Drug: Divalproex Sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex Sodium DR Tablets 500 mg
Study: NCT04651556
Drug: Magnesium Sulfate & bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
Study: NCT04326153
Drug: Sintilimab Injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total.
Study: NCT03384654
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
Study: NCT03384654
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
Study: NCT03384654
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
Study: NCT00225277
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Study: NCT00225277
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Study: NCT00615173
Drug: tacrolimus (FK506)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Study: NCT00383747
Drug: transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14mg transdermal nicotine application
Study: NCT00383747
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14mg transdermal nicotine application
Study: NCT03228277
Drug: Olmutinib
Normalized name: olmutinib
DrugBank: Olmutinib (DB13164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
Study: NCT04636957
Drug: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution
Normalized name: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% otic solution
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.